Medical product company, Genovi sees its rights issue fully subscribed

Tuesday, 22 May 2012
Genovis’ rights issue is fully subscribed and 81percent of the shares are subscribed with preferential rights.
In a press release from the company, the rights issue raised about Skr 12.1 million before issue expenses for Genovis. Statements of account will be sent on May 22, 2012, to allot shares subscribed without preferential rights, the company writes in a press release.

Genovis develops and sells innovative technologies from two unique product portfolios. The first includes enzymes that facilitate development and quality control for applications such as antibody-based drugs. The products launched to date are aimed at customers who work with development of drugs, new diagnostic methods and basic research.
By Scancomark.se Team

What do you think about this article or us? Please leave a comment. Thank you!